0001415889-23-006833.txt : 20230425 0001415889-23-006833.hdr.sgml : 20230425 20230425160958 ACCESSION NUMBER: 0001415889-23-006833 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230421 FILED AS OF DATE: 20230425 DATE AS OF CHANGE: 20230425 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Utter Christine Marie CENTRAL INDEX KEY: 0001707685 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 23844965 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 form4-04252023_080440.xml X0407 4 2023-04-21 0001070081 PTC THERAPEUTICS, INC. PTCT 0001707685 Utter Christine Marie C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 false true false false SVP, FINANCE & CAO 1 Common Stock 2023-04-21 4 M 0 4321 33.02 A 42380 D Common Stock 2023-04-21 4 S 0 4321 55.0511 D 38059 D Common Stock 2023-04-21 4 M 0 371 33.02 A 38430 D Common Stock 2023-04-21 4 S 0 351 55.0920 D 38079 D Common Stock 2023-04-21 4 S 0 20 55.64 D 38059 D Stock Option (Right to Buy) 33.02 2023-04-21 4 M 0 4321 33.02 D 2029-01-21 Common Stock 4321 0 D Stock Option (Right to Buy) 33.02 2023-04-21 4 M 0 371 33.02 D 2029-01-21 Common Stock 371 0 D Stock Option (Right to Buy) 51 2025-01-02 Common Stock 17800 17800 D Stock Option (Right to Buy) 51.16 2030-01-28 Common Stock 23800 23800 D Stock Option (Right to Buy) 66.49 2031-01-05 Common Stock 50750 50750 D Stock Option (Right to Buy) 38.10 2032-01-06 Common Stock 43500 43500 D Stock Option (Right to Buy) 39.42 2033-01-04 Common Stock 32500 32500 D This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.50 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. /s/ Avraham S. Adler, Attorney-in-Fact 2023-04-25